Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2001 3
2002 3
2003 11
2004 13
2005 33
2006 47
2007 44
2008 37
2009 26
2010 28
2011 20
2012 18
2013 16
2014 19
2015 20
2016 18
2017 19
2018 10
2019 10
2020 40
2021 44
2022 26
2023 18
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

486 results

Results by year

Filters applied: . Clear all
Page 1
Ciclesonide.
[No authors listed] [No authors listed] 2024 May 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2024 May 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000518 Free Books & Documents. Review.
Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19: A Randomized Clinical Trial.
Clemency BM, Varughese R, Gonzalez-Rojas Y, Morse CG, Phipatanakul W, Koster DJ, Blaiss MS. Clemency BM, et al. JAMA Intern Med. 2022 Jan 1;182(1):42-49. doi: 10.1001/jamainternmed.2021.6759. JAMA Intern Med. 2022. PMID: 34807241 Free PMC article. Clinical Trial.
INTERVENTIONS: Participants were randomly assigned to receive ciclesonide MDI, 160 mug per actuation, for a total of 2 actuations twice a day (total daily dose, 640 mug) or placebo for 30 days. ...The median time to alleviation of all COVID-19-related symptoms was 19.0 day …
INTERVENTIONS: Participants were randomly assigned to receive ciclesonide MDI, 160 mug per actuation, for a total of 2 actuations twi …
Ciclesonide and the treatment of asthma.
Korenblat PE. Korenblat PE. Expert Opin Pharmacother. 2010 Feb;11(3):463-79. doi: 10.1517/14656560903575647. Expert Opin Pharmacother. 2010. PMID: 20102309 Review.
Moreover, studies have found that ciclesonide is as effective as other ICSs in establishing and controlling disease symptoms. Controlled clinical trials also showed that ciclesonide is associated with minimal systemic and local treatment-related adverse events. ...
Moreover, studies have found that ciclesonide is as effective as other ICSs in establishing and controlling disease symptoms. Control …
Ciclesonide.
Reynolds NA, Scott LJ. Reynolds NA, et al. Drugs. 2004;64(5):511-9; discussion 520-1. doi: 10.2165/00003495-200464050-00005. Drugs. 2004. PMID: 14977388 Clinical Trial.
Inhaled ciclesonide was generally well tolerated in patients with asthma. Ciclesonide did not suppress biochemical markers of adrenal function in 52-week studies. The long-term (>52 weeks) systemic effects of ciclesonide remain unknown....
Inhaled ciclesonide was generally well tolerated in patients with asthma. Ciclesonide did not suppress biochemical markers of …
Review of efficacy of ciclesonide for the treatment of asthma in children.
Blaiss M, Berger W, Chipps B, Hernandez-Trujillo V, Phipatanakul W, Steward K. Blaiss M, et al. Allergy Asthma Proc. 2021 Nov 1;42(6):461-470. doi: 10.2500/aap.2021.42.210062. Allergy Asthma Proc. 2021. PMID: 34871153 Review.
Background: Ciclesonide (CIC) is an inhaled corticosteroid (ICS) approved for the maintenance treatment of asthma in patients ages 12 years. ...
Background: Ciclesonide (CIC) is an inhaled corticosteroid (ICS) approved for the maintenance treatment of asthma in patients ages 12 …
Ciclesonide: A Pro-Soft Drug Approach for Mitigation of Side Effects of Inhaled Corticosteroids.
Mukker JK, Singh RSP, Derendorf H. Mukker JK, et al. J Pharm Sci. 2016 Sep;105(9):2509-2514. doi: 10.1016/j.xphs.2016.05.004. Epub 2016 Jun 21. J Pharm Sci. 2016. PMID: 27339407 Review.
Ciclesonide, a pro-soft drug, is converted to an active metabolite desisobutyryl-ciclesonide in the lungs. The anti-inflammatory effect of desisobutyryl-ciclesonide is much higher than ciclesonide, and therefore, the local effect of the metabolite is h …
Ciclesonide, a pro-soft drug, is converted to an active metabolite desisobutyryl-ciclesonide in the lungs. The anti-inflammato …
Ciclesonide nasal spray: in allergic rhinitis.
Dhillon S, Wagstaff AJ. Dhillon S, et al. Drugs. 2008;68(6):875-83. doi: 10.2165/00003495-200868060-00009. Drugs. 2008. PMID: 18416590 Review.
Ciclesonide nasal spray delivers the corticosteroid ciclesonide as a hypotonic spray via a metered-dose manual pump. Systemic exposure to ciclesonide and its active metabolite desisobutyryl-ciclesonide is low after intranasal administration. ...
Ciclesonide nasal spray delivers the corticosteroid ciclesonide as a hypotonic spray via a metered-dose manual pump. Systemic …
Ciclesonide versus other inhaled corticosteroids for chronic asthma in children.
Kramer S, Rottier BL, Scholten RJ, Boluyt N. Kramer S, et al. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD010352. doi: 10.1002/14651858.CD010352. Cochrane Database Syst Rev. 2013. PMID: 23450613 Free article. Review.
SELECTION CRITERIA: Randomised controlled parallel or cross-over studies were eligible for the review. We included studies comparing ciclesonide with other corticosteroids both at nominally equivalent doses or lower doses of ciclesonide. ...There is a need for studi …
SELECTION CRITERIA: Randomised controlled parallel or cross-over studies were eligible for the review. We included studies comparing cicl …
Ciclesonide: a novel inhaled corticosteroid.
Humbert M. Humbert M. Expert Opin Investig Drugs. 2004 Oct;13(10):1349-60. doi: 10.1517/13543784.13.10.1349. Expert Opin Investig Drugs. 2004. PMID: 15461563 Review.
Ciclesonide is an agent that is inactive until it reaches its target site, the lung, where it is converted to its active metabolite desisobutyryl-ciclesonide. In addition, other favourable pharmacokinetic and pharmacodynamic characteristics such as high protein bind …
Ciclesonide is an agent that is inactive until it reaches its target site, the lung, where it is converted to its active metabolite d …
Ciclesonide: a novel inhaled corticosteroid for asthma.
Christie P. Christie P. Drugs Today (Barc). 2004 Jul;40(7):569-76. doi: 10.1358/dot.2004.40.7.850475. Drugs Today (Barc). 2004. PMID: 15510231 Review.
Ciclesonide is a parent compound that is converted locally in airways by esterases to produce the active metabolite, desisobutyryl-ciclesonide (des-CIC). ...If any ciclesonide enters the circulation, it is highly protein bound (99%) and extensively metabolize …
Ciclesonide is a parent compound that is converted locally in airways by esterases to produce the active metabolite, desisobutyryl- …
486 results

Searches related to "ciclesonide"